The Tolerance of CANTIVATE in Young Patients

The tolerance of this regimen was much greater than in GLOW. 95% of patients actually completed all 12 cycles of the combination treatment or were eligible for randomization. Iplus-V, while it is tolerable, does have increased diarrhea, does have some neutropenia and cytopenia issues. We do see these cardiac issues but clearly is much more tolerated in the younger patient population where we don't need to be giving our 80, 85, 90 year old patients combination treatments.